<DOC>
	<DOCNO>NCT00685373</DOCNO>
	<brief_summary>This provide long-term safety efficacy data ACZ885 ( fully human anti-interleukin-1β [ anti-IL-1β ] monoclonal antibody ) give injection subcutaneously patient participate CACZ885A2102 ( NCT00487708 ) , CACZ885D2201 ( NCT00685373 ) CACZ885D2304 ( NCT00465985 ) study newly identify patient follow cryopyrin-associated periodic syndrome : Familial Cold Autoinflammatory Syndrome , Muckle-Wells Syndrome Neonatal Onset Multisystem Inflammatory Disease . The duration study 6 month maximum duration 2 year</brief_summary>
	<brief_title>Efficacy Safety ACZ885 Patients With Following Cryopyrin-associated Periodic Syndromes : Familial Cold Autoinflammatory Syndrome , Muckle-Wells Syndrome , Neonatal Onset Multisystem Inflammatory Disease</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Eosinophilia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Male female patient least 3 year age 2 . Diagnosis Familial Cold Autoinflammatory Syndrome , MuckleWells Syndrome Neonatal Onset Multisystem Inflammatory Disease . Prior agreement Investigator Novartis study eligibility require patient molecular diagnosis NALP3 mutation available ( either test perform , test perform negative ) upon study entry . For patient molecularly test NALP3 mutation , molecular testing perform course study 3 . For patient anakinra therapy investigational IL1 block therapy , treatment discontinue prior baseline visit . 4 . Patients CACZ885A2102 study may enter study . However , dose Visit 2 ( Baseline Visit ) occur either 1 ) patient experience disease flare 2 ) least two month elapse last injection even absence flare , whichever early . 5 . Patients complete CACZ885D2304 study may enter study 6 . Patients complete CACZ885D2201 study may enter study 7 . Patients discontinue CACZ885A2102 , CACZ885D2201 CACZ885D2304 study Investigator 's judgment ( prior agreement Novartis ) continue treatment ACZ885 study consider appropriate . 1 . Participation clinical investigation within 4 week prior dose longer required local regulation exception trial anakinra , investigational IL1 block therapy , and/or ACZ885 . 2 . History immunocompromised , include positive HIV screening ( ELISA Western blot ) test result . 3 . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody test result allow . 4 . No live vaccination within 3 month prior start trial , trial , 3 month follow last dose . 5 . History recurrent and/or evidence active bacterial , fungal , viral infection . 6 . Positive tuberculin skin test reaction ( PPD 5 tuberculin unit accord local standard practice ) ( &gt; = 5 mm induration ) 48 72 hour administration screen visit within 2 month prior screen visit . Patients positive PPD skin test documentation BCG vaccination , low environmental risk tuberculosis ( TB ) infection reactivation , negative chest Xray include . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cryopyrin-associated periodic syndrome ( CAPS ) :</keyword>
	<keyword>Familial Cold Autoinflammatory Syndrome ( FCAS ) ,</keyword>
	<keyword>Muckle-Wells Syndrome ( MWS ) ,</keyword>
	<keyword>MWS overlap symptom Neonatal Onset Multisystem Inflammatory Disease ( NOMID ) Neonatal Onset Multisystem Inflammatory Disease ( NOMID ) ,</keyword>
	<keyword>child ,</keyword>
	<keyword>systemic autoinflammatory disease ,</keyword>
	<keyword>CIAS-1 gene ,</keyword>
	<keyword>NALP-3 ,</keyword>
	<keyword>ACZ885 ,</keyword>
	<keyword>human monoclonal anti-human interleukin-1beta ( IL-1beta ) ,</keyword>
	<keyword>antibody ,</keyword>
	<keyword>autosomal dominant ,</keyword>
	<keyword>familial autoinflammatory syndrome</keyword>
</DOC>